SAN

91.87

-0.21%↓

SHL.DE

48.92

-0.61%↓

ARGX

504.8

+0.36%↑

FRE

43.18

+0.63%↑

ONC.US

228.61

+1.33%↑

SAN

91.87

-0.21%↓

SHL.DE

48.92

-0.61%↓

ARGX

504.8

+0.36%↑

FRE

43.18

+0.63%↑

ONC.US

228.61

+1.33%↑

SAN

91.87

-0.21%↓

SHL.DE

48.92

-0.61%↓

ARGX

504.8

+0.36%↑

FRE

43.18

+0.63%↑

ONC.US

228.61

+1.33%↑

SAN

91.87

-0.21%↓

SHL.DE

48.92

-0.61%↓

ARGX

504.8

+0.36%↑

FRE

43.18

+0.63%↑

ONC.US

228.61

+1.33%↑

SAN

91.87

-0.21%↓

SHL.DE

48.92

-0.61%↓

ARGX

504.8

+0.36%↑

FRE

43.18

+0.63%↑

ONC.US

228.61

+1.33%↑

Search

Ion Beam Applications

Open

11.2 -1.58

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.12

Max

11.38

Belangrijke statistieken

By Trading Economics

Inkomsten

30M

20M

Verkoop

85M

292M

K/W

Sectorgemiddelde

42.815

56.602

Dividendrendement

1.49

Winstmarge

6.719

Werknemers

2,118

EBITDA

24M

24M

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.49%

2.45%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

31M

340M

Vorige openingsprijs

12.78

Vorige sluitingsprijs

11.2

Ion Beam Applications Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 sep 2024, 06:28 UTC

Acquisities, Fusies, Overnames

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Peer Vergelijking

Prijswijziging

Ion Beam Applications Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.